This is in line with the results of a Cochrane review by Fullerton showing only a minor (but clinically irrelevant) benefit of short-acting insulin analogues on HbA1c in people with type 1 diabetes (i.e. − 0.15% in favour of insulin analogues) [20]. Here, INS is linked to type 1 diabetes mellitus.